Stock 4882 PERSEUS PROTEOMICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Perseus Proteomics Inc.

Equities

4882

JP3836800007

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-06-05 am EDT 		5-day change 1st Jan Change
310 JPY -1.59% Intraday chart for Perseus Proteomics Inc. +0.65% -49.84%
May. 10 Perseus Proteomics Inc. Announces on Delay in the End of Phase I Clinical Trial for Polycythemia Vera CI
Mar. 07 Perseus Proteomics Inc. announced that it has received ¥1.566 million in funding from Barclays Bank PLC (Tokyo Branch) CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Perseus Proteomics Inc. Announces on Delay in the End of Phase I Clinical Trial for Polycythemia Vera
Perseus Proteomics Inc. Reports Earnings Results for the Nine Months Ended December 31, 2023
Perseus Proteomics Inc. Announces on Delay in the End of Phase I Clinical Trial for Polycythemia Vera
Perseus Proteomics Inc. Reports Earnings Results for the Half Year Ended September 30, 2023
Perseus Proteomics Inc. Announces Completion of Patients Enrollment in Phase I Clinical Trial for Polycythemia Vera (PV)
Perseus Proteomics Inc. Announces Sales Launch of New Antibodies/Reagents
Perseus Proteomics, Inc. Announces Provision of Antibody Research Support Service Through Single Cell Cloning Technology
Perseus Proteomics Inc. Announces on Dosing of the First Patient in Phase I/II Clinical Trial for Aggressive NK-Cell Leukemia
Perseus Proteomics, Inc. Announces MOU Agreement on Joint Research on Super-Neutralizing Antibody with University of Toyama and Toyama Prefecture
Perseus Proteomics Inc. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2024
Perseus Proteomics Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023
Perseus Proteomics Inc. Announces the Interim Report of Phase I Clinical Trial of PPMX-T003
Perseus Proteomics Inc. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2024
Perseus Proteomics Inc. Reports Earnings Results for the Full Year Ended March 31, 2023
Perseus Proteomics Inc. Updates Financial Forecast for the Year 2022
Perseus Proteomics Inc. Announces That PMDA Has Finished Investigation of the Clinical Trial Notification of the Phase I/II Investigator-Led Clinical Trial
Perseus Proteomics Inc. Submits the Clinical Trial Notification of the Phase I/II Investigator-Led Clinical Trial Among Aggressive Nk-Cell Leukemia Patients Using In-Development Anti-Transferrin Receptor Antibody PPMX-T003 as A Therapeutic to the PMDA by Hiroshima University Hospital
Perseus Proteomics Inc. Reports Earnings Results for the Nine Months Ended December 31, 2022
Perseus Proteomics Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023
Perseus Proteomics Inc. Announces Extension of Phase I Clinical Trial of PPMX-T003 among Polycythemia Vera Patients
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4882 Stock
  4. News Perseus Proteomics Inc.
  5. Other languages